BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Leukemia AND SETBP1, Q9UEF3, Q6P6C3, A6H8W5, Q9Y6X0, 26040, SEB, KIAA0437, ENSG00000152217 AND Prognosis
38 results:

  • 1. [The Correlation of Gene Mutation and Clinical Characteristics in Patients with Myelodysplastic Syndrome and Prognostic Analysis].
    Zhang WW; Zhang YL; Ren CC; Wu TK; Liu B
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Feb; 32(1):176-183. PubMed ID: 38387918
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Subclones with variants of uncertain clinical significance might contribute to ineffective hemopoiesis and leukemia predisposition.
    Giudice V; Serio B; Errichiello S; Ferrara I; Galdiero A; Bertolini A; Visconti R; De Novellis D; Guariglia R; Luponio S; Morini D; Della Corte AM; Sessa AM; Verdesca F; Langella M; Izzo B; Selleri C
    Eur J Haematol; 2023 Nov; 111(5):729-741. PubMed ID: 37501402
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. setbp1 is dispensable for normal and malignant hematopoiesis.
    Tanaka A; Nishimura K; Saika W; Kon A; Koike Y; Tatsumi H; Takeda J; Nomura M; Zang W; Nakayama M; Matsuda M; Yamazaki H; Fukumoto M; Ito H; Hayashi Y; Kitamura T; Kawamoto H; Takaori-Kondo A; Koseki H; Ogawa S; Inoue D
    Leukemia; 2023 Sep; 37(9):1802-1811. PubMed ID: 37464069
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Co-occurring mutations in ASXL1, SRSF2, and setbp1 define a subset of myelodysplastic/ myeloproliferative neoplasm with neutrophilia.
    Jain T; Ware AD; Dalton WB; Pasca S; Tsai HL; Gocke CD; Gondek LP; Xian RR; Borowitz MJ; Levis MJ
    Leuk Res; 2023 Aug; 131():107345. PubMed ID: 37354804
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Myelodysplastic/myeloproliferative neoplasms-unclassifiable with isolated isochromosome 17q represents a distinct clinico-biologic subset: a multi-institutional collaborative study from the Bone Marrow Pathology Group.
    Kanagal-Shamanna R; Orazi A; Hasserjian RP; Arber DA; Reichard K; Hsi ED; Bagg A; Rogers HJ; Geyer J; Darbaniyan F; Do KA; Devins KM; Pozdnyakova O; George TI; Cin PD; Greipp PT; Routbort MJ; Patel K; Garcia-Manero G; Verstovsek S; Medeiros LJ; Wang SA; Bueso-Ramos C
    Mod Pathol; 2022 Apr; 35(4):470-479. PubMed ID: 34775472
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Distinct Mutation Landscapes Between Acute Myeloid leukemia With Myelodysplasia-Related Changes and De Novo Acute Myeloid leukemia.
    Gao Y; Jia M; Mao Y; Cai H; Jiang X; Cao X; Zhou D; Li J
    Am J Clin Pathol; 2022 May; 157(5):691-700. PubMed ID: 34664628
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Mutational landscape of chronic myelomonocytic leukemia and its potential clinical significance.
    Han W; Zhou F; Wang Z; Hua H; Qin W; Jia Z; Cai X; Chen M; Liu J; Chao H; Lu X
    Int J Hematol; 2022 Jan; 115(1):21-32. PubMed ID: 34449040
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Mutations in chronic myelomonocytic leukemia and their prognostic relevance.
    Jian J; Qiao Y; Li Y; Guo Y; Ma H; Liu B
    Clin Transl Oncol; 2021 Sep; 23(9):1731-1742. PubMed ID: 33861431
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. CSF3R T618I, setbp1 G870S, SRSF2 P95H, and ASXL1 Q780* tetramutation co-contribute to myeloblast transformation in a chronic neutrophilic leukemia.
    Qian Y; Chen Y; Li X
    Ann Hematol; 2021 Jun; 100(6):1459-1461. PubMed ID: 33822276
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Differential U2AF1 mutation sites, burden and co-mutation genes can predict prognosis in patients with myelodysplastic syndrome.
    Wang H; Guo Y; Dong Z; Li T; Xie X; Wan D; Jiang Z; Yu J; Guo R
    Sci Rep; 2020 Oct; 10(1):18622. PubMed ID: 33122737
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Additional gene mutations may refine the 2017 European leukemiaNet classification in adult patients with de novo acute myeloid leukemia aged <60 years.
    Eisfeld AK; Kohlschmidt J; Mims A; Nicolet D; Walker CJ; Blachly JS; Carroll AJ; Papaioannou D; Kolitz JE; Powell BE; Stone RM; de la Chapelle A; Byrd JC; Mrózek K; Bloomfield CD
    Leukemia; 2020 Dec; 34(12):3215-3227. PubMed ID: 32461631
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. [Analysis of Clinical Features and prognosis of Patients with Chronic Neutrophil leukemia].
    Guo YJ; Wang Y; Wang LH; Zuo YB; Niu ZY; Lin FR; Zhang JY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Feb; 28(1):82-87. PubMed ID: 32027257
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Next-generation sequencing reveals unique combination of mutations in cis of CSF3R in atypical chronic myeloid leukemia.
    Yun JW; Yoon J; Jung CW; Lee KO; Kim JW; Kim SH; Kim HJ
    J Clin Lab Anal; 2020 Feb; 34(2):e23064. PubMed ID: 31692115
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. [Characterization of mutational pattern of patients with core-binding factor acute myeloid leukemia].
    He J; Chao H; Zhou M; Lu X; Chen T; Yang J; Jiang N; Zhang R
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2019 Jul; 36(7):657-661. PubMed ID: 31302905
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Mutational spectrum and associations with clinical features in patients with acute myeloid leukaemia based on next‑generation sequencing.
    Li Y; Lv X; Ge X; Yuan D; Ding M; Zhen C; Zhao W; Liu X; Wang X; Xu H; Li Y; Wang X
    Mol Med Rep; 2019 May; 19(5):4147-4158. PubMed ID: 30942411
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Coexisting of bone marrow fibrosis, dysplasia and an X chromosomal abnormality in chronic neutrophilic leukemia with CSF3R mutation: a case report and literature review.
    Wu XB; Wu WW; Zhou Y; Wang X; Li J; Yu Y
    BMC Cancer; 2018 Mar; 18(1):343. PubMed ID: 29587671
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Chronic neutrophilic leukemia: 2018 update on diagnosis, molecular genetics and management.
    Elliott MA; Tefferi A
    Am J Hematol; 2018 Aug; 93(4):578-587. PubMed ID: 29512199
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. MLL-rearranged acute myeloid leukemia: Influence of the genetic partner in allo-HSCT response and prognostic factor of MLL 3' region mRNA expression.
    Burillo-Sanz S; Morales-Camacho RM; Caballero-Velázquez T; Carrillo E; Sánchez J; Pérez-López O; Pérez de Soto I; González Campos J; Prats-Martín C; Bernal R; Vargas MT
    Eur J Haematol; 2018 May; 100(5):436-443. PubMed ID: 29384595
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Only setbp1 hotspot mutations are associated with refractory disease in myeloid malignancies.
    Winkelmann N; Schäfer V; Rinke J; Kaiser A; Ernst P; Scholl S; Hochhaus A; Ernst T
    J Cancer Res Clin Oncol; 2017 Dec; 143(12):2511-2519. PubMed ID: 28913558
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Somatic setbp1 mutations in myeloid neoplasms.
    Makishima H
    Int J Hematol; 2017 Jun; 105(6):732-742. PubMed ID: 28447248
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 2.